Influence of the timing of biological treatment initiation on Juvenile Idiopathic Arthritis long-term outcomes
Main finding · Remission off medication (drug-free remission)Result — go to the resultOR for achieving remission off medication 0.24 95% CI 0.06–0.92Authors' conclusion
Later initiation of bDMARDs in JIA is associated with a greater physical disability, worse HRQoL, and lower chance of drug-free remission in adulthood.
Study context
- Population
- Adult juvenile idiopathic arthritis (JIA) patients registered in the Rheumatic Diseases Portuguese Register (Reuma.pt), ever treated with biological disease-modifying antirheumatic drug (bDMARD); median disease duration 20.3 years
- Participants
- 361 patients
- Exposure
- Time from JIA onset to bDMARD initiation: ≤ 2 years vs 2-5 years vs > 5 years
- Outcome
- Clinical remission (on/off medication), physical disability (HAQ-DI), health-related quality of life (HRQoL) (SF-36) and joint surgeries
- Follow-up
- Last visit
Methodological detailsregistry-based (Reuma.pt), regression models
- Registry-based (Reuma.pt)
- Regression models
Main finding
Remission off medication (drug-free remission)
OR for achieving remission off medication
0.24
95% CI 0.06–0.92
P = 0.038
> 5 years
OR for achieving remission off medication 0.24 (95% CI 0.06–0.92); P = 0.038
As reported in the abstract
Observational data: associations, not effects.
Further findings
Disease status at last visit (whole cohort)
- Active disease
- 40.4%
- Remission on medication
- 35.1%
- Drug-free remission
- 24.4%
- Some degree of physical disability
- 71%
Original publication
Influence of the timing of biological treatment initiation on Juvenile Idiopathic Arthritis long-term outcomes. Arthritis Res Ther. Published 21 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →